The Synthetic Cannabinoid WIN55212-2 Decreases the Intraocular Pressure in Human Glaucoma Resistant to Conventional Therapies

European Journal of Neuroscience - United Kingdom
doi 10.1046/j.0953-816x.2000.01401.x
Full Text
Abstract

Available in full text

Categories
Neuroscience
Date
Authors
Publisher

Wiley

Related search

24-Hour Intraocular Pressure and Ocular Perfusion Pressure in Glaucoma

Survey of Ophthalmology
Ophthalmology
2013English

Intraocular Pressure: Protagonist or Supporting Actor in Glaucoma?

International Journal of Ophthalmic Research
2015English

Diurnal Intraocular Pressure Variation in Low-Tension Glaucoma

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
1994English

Relationship Between Nocturnal Intraocular Pressure Elevation and Diurnal Intraocular Pressure Level in Normal-Tension Glaucoma Patients

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2015English

Evolution the Concepts of Role of Intraocular Pressure in Glaucoma Progression (Review)

Oftalmologiya
Ophthalmology
2016English

Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors

Journal of Pharmacology and Experimental Therapeutics
Molecular MedicinePharmacology
2018English

Intraocular Pressure Reduction in Neovascular Glaucoma Using Ex-Press Implantation

Sohag Medical Journal
2018English

Prognostic Factor Analysis of Intraocular Pressure With Neovascular Glaucoma

Journal of Ophthalmology
Ophthalmology
2016English

Effects of Glaucoma Medications on the Cardiorespiratory and Intraocular Pressure Status of Newly Diagnosed Glaucoma Patients

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy